Vasopressin (AVP) Peptide Research: V1a/V1b/V2 Receptor Pharmacology, Social Memory Circuits, and Preclinical Cardiovascular Evidence

Arginine vasopressin is a disulfide-bridged nonapeptide, Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2, acting at three receptors with three different couplings, and vasopressin peptide research is unusual in that the cleanest causal evidence in the field comes from gene replacement rather than from pharmacology. The V1a receptor drives vasoconstriction through Gq, the V1b receptor potentiates pituitary ACTH release, and the V2 receptor drives renal water reabsorption through Gs. Its near-identity with oxytocin, differing only at positions 3 and 8, is both the reason the two systems are studied together and the reason receptor attribution is difficult. Vasopressin is a reference compound discussed here for its pharmacology; it is not an item in the Maple Research Labs catalogue.

Disclaimer: For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use. The information presented here is drawn from published scientific literature and is intended solely for educational reference.

Structure and Chemistry

The molecular formula is C46H65N15O12S2 with an average mass of approximately 1084.2 Da, CAS 113-79-1. Phenylalanine at position 3 and arginine at position 8 are what distinguish it from oxytocin, which carries isoleucine and leucine at those positions. That two-residue difference produces measurable cross-reactivity at oxytocin receptors at high concentrations, which is a real confound in binding work and the reason subtype-selective ligands rather than the native peptides are used for receptor attribution.

The Cys1-Cys6 disulfide defines the ring and is required for receptor recognition; reduced or alkylated analogues lose affinity across all three subtypes. That has a direct analytical consequence. A preparation containing partially reduced or linear material will read as low potency rather than as impure, because the contaminant is inactive rather than differently active, so the concentration-response curve shifts right with no change in its shape. Confirming the intact cyclic structure is therefore not an optional extra check for this peptide, it is what makes the potency number meaningful. The analysis of oxytocin degradation and heat stability follows the same disulfide chemistry through beta-elimination to trisulfide, tetrasulfide and dimer products and sets out what a certificate has to show for a nonapeptide of this class.

Vasopressin is produced from a precursor that also yields neurophysin II and the C-terminal glycopeptide copeptin. Copeptin is co-secreted in equimolar amounts and is far more stable in plasma, which is why it has become the practical surrogate measurement in research samples where vasopressin itself is difficult to quantify.

Receptor Subtypes

V1a couples through Gq/11 to phospholipase C, raising inositol trisphosphate and diacylglycerol, elevating intracellular calcium and activating protein kinase C. In vascular smooth muscle that produces vasoconstriction. The receptor is also densely expressed in lateral septum, bed nucleus of the stria terminalis and amygdala, which is what places it in social behaviour circuitry.

V1b is also Gq/11-coupled and concentrated in anterior pituitary corticotrophs and limbic structures, where it potentiates corticotropin-releasing factor-driven ACTH release. Parvocellular paraventricular neurons co-express vasopressin and CRF and release both into the hypophyseal portal circulation, and the relative contribution of vasopressin rises under chronic stress. Aguilera’s work is the standard reference for that shift (Regulatory Peptides 2000, 96:23-29, PMID 11102648; Stress 2004, 7:75-83, PMID 15512850; Progress in Brain Research 2008, 170:29-39, PMID 18655869). An earlier version of this page attributed a specific restraint stress experiment with a stated group size to a 2002 Regulatory Peptides paper; the located Aguilera papers on this question are the three above.

V2 couples through Gs to adenylyl cyclase in collecting duct principal cells, phosphorylating aquaporin-2 at Ser256 and driving its trafficking to the apical membrane. This is the best-understood arm of the system and the basis for the vaptan antagonists used to create controlled states of aquaporin insufficiency in renal physiology models.

Social Recognition and the Lateral Septum

The knockout phenotype was reported by Bielsky and colleagues in Neuropsychopharmacology (2004, 29:483-493, PMID 14647484), not in Neuron as an earlier version of this page stated. Male mice lacking functional V1a receptor showed markedly reduced anxiety-like behaviour and profound impairment of social recognition while performing normally on spatial and nonsocial olfactory learning and memory tasks, which is what establishes the deficit as social rather than general. Acute central vasopressin robustly stimulated stereotypical scratching and autogrooming in wild-type but not knockout males. Vasopressin and oxytocin mRNA and oxytocin receptor binding were similar between genotypes, ruling out compensatory changes in the sister system as the explanation.

The localisation came a year later, and the method matters (Neuron 2005, 47:503-513, PMID 16102534). Site-specific injection of a V1a-selective antagonist showed the lateral septum, but not the medial amygdala, is critical for social recognition. Re-expressing the receptor in the lateral septum of knockout mice using a viral vector produced a complete rescue of social recognition, and overexpressing it in the lateral septum of wild-type mice potentiated social recognition and mildly increased anxiety-related behaviour. An earlier version of this page described partial restoration by vasopressin microinfusion at stated doses per site; the published result is genetic re-expression with complete rescue, which is a stronger claim and a different experiment. The bidirectional result, loss with antagonist and gain with overexpression, is what makes this one of the better-supported structure-function links in behavioural neuropeptide work.

The vole literature is frequently compressed into a single citation and should not be. Young and colleagues (Nature 1999, 400:766-768, PMID 10466725) showed that centrally administered vasopressin increases affiliative behaviour in the monogamous prairie vole but not in the promiscuous montane vole, and that mice transgenic for the prairie vole receptor gene acquire both a prairie-vole-like receptor binding pattern and increased affiliative behaviour after vasopressin. The microsatellite result is a separate paper: Hammock and Young (Science 2005, 308:1630-1634, PMID 15947188) showed that individual alleles of a repetitive polymorphic microsatellite in the 5′ region of the prairie vole avpr1a gene modify expression in vitro and predict both receptor distribution and sociobehavioural traits in vivo. An earlier version of this page merged the two and attached group sizes that appear in neither.

V1b Antagonism and the Stress Axis

SSR149415 is the tool compound for isolating the V1b contribution, and its characterising paper is Griebel and colleagues in the Proceedings of the National Academy of Sciences (2002, 99:6370-6375, PMID 11959912), not a 2005 paper. What that study actually reports is behavioural rather than endocrine. In classical anxiety tests including punished drinking, elevated plus maze and light/dark, the compound produced anxiolytic-like activity from 1 to 30 mg/kg but with a smaller effect than the diazepam positive control. In models involving traumatic stress exposure, the social defeat paradigm and the defence test battery, the anxiolytic-like activity was clear-cut over the same dose range. In forced swimming it produced antidepressant-like effects in both normal and hypophysectomised rats, and that hypophysectomy control is the important detail, because it shows the behavioural effect does not require an intact pituitary and therefore is not simply downstream of reduced ACTH. In chronic mild stress in mice, repeated administration over 39 days improved physical state, anxiety, despair and loss of coping behaviour. An earlier version of this page reported 45 to 60 percent ACTH reductions to interleukin-1 beta and forced swim challenge with a stated group size; those figures are not in that paper. The broader case for V1b antagonists in stress-related disorders is reviewed in Current Pharmaceutical Design (2005, 11:1549-1559, PMID 15892661).

Cardiovascular Pharmacology

V1a-mediated vasoconstriction is the peripheral action, and vasopressin is among the more potent endogenous constrictors in isolated vessel preparations, with responses appearing in the picomolar range. The pharmacological attribution is straightforward because SR49059 is V1a-selective, so loss of the response under antagonist confirms the subtype rather than V2 or oxytocin receptor involvement. A canine haemorrhagic shock experiment with specific mean arterial pressures and an infusion rate in units per kilogram per minute, attributed on this page to Landry and colleagues in Circulation in 1997, could not be verified against that citation and has been removed; that paper concerns vasopressin deficiency in vasodilatory shock in humans, which is a different model and a clinical rather than preclinical context.

Cardiac V1a signalling through ERK1/2 and p38 MAPK, producing sarcomeric reorganisation and a hypertrophic transcriptional signature in neonatal rat ventricular cardiomyocytes, is reported in the cardiac hypertrophy literature and remains an in vitro finding. Extrapolating it to a cardioprotective rationale for V1a antagonism requires in vivo confirmation under pressure overload, which is the appropriate caveat to carry.

Analytical and Study Design Considerations

Quantifying vasopressin in biological matrices is genuinely difficult, and the difficulty is structural rather than incidental. Physiological plasma concentrations sit in the low picogram per millilitre range, the peptide is cleared rapidly, and it adsorbs to glass. Radioimmunoassay protocols therefore require extraction and concentration, typically acetone precipitation or C18 solid-phase extraction, before quantification, and mass spectrometric methods on extracted plasma offer better specificity against co-eluting matrix components. This is the practical reason copeptin is measured instead in many designs.

For binding work, polypropylene vessels show substantially lower non-specific binding than glass, and adding a small amount of bovine serum albumin to incubation buffers reduces surface adsorption artefacts. Batch identity should be confirmed by mass and the intact disulfide verified, for the reason set out above. General methodology is covered in the discussion of HPLC testing for peptide purity and in the treatment of mass spectrometry for identity confirmation.

On study design, the separation of central from peripheral action is the recurring methodological problem. Peripheral administration engages V1a in vasculature and V2 in kidney, and cardiovascular and fluid-balance changes can produce behavioural effects that have nothing to do with central receptors. Central routes are preferred for behavioural work for that reason, and peripheral studies drawing central conclusions need explicit controls.

Where a batch of a compound in our catalogue has been tested, the independent laboratory report is published on the certificates of analysis page, which also lists the compounds still awaiting a report. Vasopressin is not a catalogue compound, and an earlier version of this page named a specific testing laboratory in connection with it. The report number and lot are what should be checked, not the laboratory’s name. The oxytocin receptor pharmacology summary covers the sister peptide, whose receptor overlap is the main confound in this literature, and the research peptide catalogue and documentation section cover the compounds that are stocked.

Citations in this article were checked against the indexed PubMed record on 20 September 2026. Corrections made in this revision: the journal for the 2004 knockout study, the method and degree of the lateral septum rescue, the separation of the 1999 Nature vole study from the 2005 Science microsatellite study, the year and reported content of the SSR149415 characterisation, and the removal of an unverifiable canine shock dataset and an unlocated 2002 Aguilera citation.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.